Literature DB >> 12172088

Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study.

A Mocroft1, R Brettle, O Kirk, A Blaxhult, J M Parkin, F Antunes, P Francioli, A D'Arminio Monforte, Z Fox, J D Lundgren.   

Abstract

OBJECTIVES: The causes of death among HIV-positive patients may have changed since the introduction of highly active antiretroviral therapy (HAART). We investigated these changes, patients who died without an AIDS diagnosis and factors relating to pre-AIDS deaths.
METHODS: Analyses of 1826 deaths among EuroSIDA patients, an observational study of 8556 patients. Incidence rates of pre-AIDS deaths were compared to overall rates. Factors relating to pre-AIDS deaths were identified using Cox regression.
RESULTS: Death rates declined from 15.6 to 2.7 per 100 person-years of follow-up (PYFU) between 1994 and 2001. Pre-AIDS incidence declined from 2.4 to 1.1 per 100 PYFU. The ratio of overall to pre-AIDS deaths peaked in 1996 at 8.4 and dropped to < 3 after 1998. The adjusted odds of dying following one AIDS defining event (ADE) increased yearly (odds ratio, 1.53; P < 0.001), conversely the odds of dying following three or more ADE decreased yearly (odds ratio, 0.79; P < 0.001). The proportion of deaths that followed an HIV-related disease decreased by 23% annually; in contrast there was a 32% yearly increase in the proportion of deaths due to known causes other than HIV-related or suicides. Injecting drug users (IDU) were significantly more likely to die before an ADE than homosexuals (relative hazard, 2.97; P < 0.0001) and patients from northern/eastern Europe (relative hazard, 2.01; P < 0.0001) were more likely to die pre-AIDS than southern patients.
CONCLUSIONS: The proportion of pre-AIDS deaths increased from 1994 to 2001; however, the incidence of pre-AIDS deaths and deaths overall declined. IDU and subjects from northern/eastern Europe had an increased risk of pre-AIDS death. HIV-positive patients live longer therefore it is essential to continue to monitor all causes of mortality to identify changes.

Entities:  

Mesh:

Year:  2002        PMID: 12172088     DOI: 10.1097/00002030-200208160-00012

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  84 in total

1.  Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects.

Authors:  B M Bergersen; L Sandvik; J N Bruun; S Tonstad
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-28       Impact factor: 3.267

2.  Postmortem findings and opportunistic infections in HIV-positive patients from a public hospital in Peru.

Authors:  Dominique Eza; Gustavo Cerrillo; David A J Moore; Cecilia Castro; Eduardo Ticona; Domingo Morales; Jose Cabanillas; Fernando Barrantes; Alejandro Alfaro; Alejandro Benavides; Arturo Rafael; Gilberto Valladares; Fernando Arevalo; Carlton A Evans; Robert H Gilman
Journal:  Pathol Res Pract       Date:  2006-09-19       Impact factor: 3.250

3.  Risk Factors Associated With Quantitative Evidence of Lung Emphysema and Fibrosis in an HIV-Infected Cohort.

Authors:  Joseph K Leader; Kristina Crothers; Laurence Huang; Mark A King; Alison Morris; Bruce W Thompson; Sonia C Flores; Michael B Drummond; William N Rom; Philip T Diaz
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-01       Impact factor: 3.731

4.  Safety and efficacy of a saquinavir-containing antiretroviral regimen in previously ART-naïve or pretreated but protease inhibitor-naïve HIV-positive patients.

Authors:  H Knechten; C Stephan; F A Mosthaf; H Jaeger; T Lutz; A Cargnico; A Stoehr; S Koeppe; C Mayr; K Schewe; E Wolf; E Wellmann; A Tappe
Journal:  Infection       Date:  2010-03-29       Impact factor: 3.553

5.  AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment.

Authors:  Kathleen Falster; Jun Yong Choi; Basil Donovan; Chris Duncombe; Brian Mulhall; David Sowden; Jialun Zhou; Matthew G Law
Journal:  AIDS       Date:  2009-11-13       Impact factor: 4.177

Review 6.  Managing HIV infection in patients older than 50 years.

Authors:  Jacqueline M McMillan; Hartmut Krentz; M John Gill; David B Hogan
Journal:  CMAJ       Date:  2018-10-22       Impact factor: 8.262

7.  Outcomes of donor-derived superinfection screening in HIV-positive to HIV-positive kidney and liver transplantation: a multicentre, prospective, observational study.

Authors:  Tania S Bonny; Charles Kirby; Craig Martens; Rebecca Rose; Niraj Desai; Michael Seisa; Christos Petropoulos; Sander Florman; Rachel J Friedman-Moraco; Nicole A Turgeon; Diane Brown; Dorry L Segev; Christine M Durand; Aaron A R Tobian; Andrew D Redd
Journal:  Lancet HIV       Date:  2020-07-27       Impact factor: 12.767

8.  Suicide mortality among people accessing highly active antiretroviral therapy for HIV/AIDS in British Columbia: a retrospective analysis.

Authors:  Jasmine Gurm; Hasina Samji; Adriana Nophal; Erin Ding; Verena Strehlau; Julia Zhu; Julio S G Montaner; Robert S Hogg; Silvia Guillemi
Journal:  CMAJ Open       Date:  2015-04-02

9.  Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001.

Authors:  Manuela García de la Hera; Inmaculada Ferreros; Julia del Amo; Patricia García de Olalla; Santiago Pérez Hoyos; Roberto Muga; Jorge del Romero; Rafael Guerrero; Ildefonso Hernández-Aguado
Journal:  J Epidemiol Community Health       Date:  2004-11       Impact factor: 3.710

Review 10.  Lung cancer in HIV infected patients: facts, questions and challenges.

Authors:  J Cadranel; D Garfield; A Lavolé; M Wislez; B Milleron; C Mayaud
Journal:  Thorax       Date:  2006-11       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.